# Professional Summary Researchers Diwan, Behera, and Murab have published a comprehensive review examining smart hydrogel-based anticancer strategies for postoperative osteosarcoma management. This work, featured in Frontiers in Biomaterials Science, addresses a critical clinical challenge in treating bone cancer following surgical intervention. Smart hydrogels represent an innovative biomaterial platform that can respond dynamically to physiological stimuli, enabling controlled drug delivery and localized therapeutic effects at tumor sites. These sophisticated materials show significant promise for preventing cancer recurrence and managing complications during the postoperative period in osteosarcoma patients. By leveraging stimuli-responsive mechanisms, smart hydrogels can enhance therapeutic efficacy while minimizing systemic toxicity associated with conventional anticancer treatments. The research underscores the potential of advanced biomaterial engineering to revolutionize postoperative cancer care, particularly for aggressive bone malignancies. This emerging approach bridges surgical oncology with materials science, offering clinicians novel tools for improving patient outcomes and quality of life following osteosarcoma resection.

Synthetic biology represents a transformative discipline merging engineering principles with biological systems to address critical medical challenges. This comprehensive review, published in Molecular Biomedicine in August 2026, examines the expanding applications of synthetic biology across biomedicine. The article explores how engineered biological components and systems are being leveraged to develop novel therapeutics, diagnostic tools, and regenerative medicine approaches. Key applications discussed include the design of programmable cells, creation of biosensors for disease detection, and development of synthetic metabolic pathways for drug production. The review highlights how synthetic biology enables precise control over cellular behavior, offering unprecedented opportunities to treat genetic disorders, cancer, and infectious diseases. By systematically integrating biological design with clinical translation, synthetic biology promises to revolutionize healthcare delivery. This open-access review provides crucial insights for researchers, clinicians, and biotech professionals seeking to understand how engineered biological systems will shape the future of medicine and personalized therapeutics.

Drug delivery has evolved from simple molecular administration to sophisticated nanomedicine platforms that control solubility, circulation time, tissue distribution, and release timing. Modern drug delivery addresses critical biopharmaceutical challenges including poor aqueous solubility, enzymatic degradation, rapid clearance, and inability to cross biological barriers like the blood-brain barrier. This progression represents a shift from "exposure control" to "precision control," beginning with sustained-release formulations that provided smoother plasma concentrations, advancing to encapsulation technologies utilizing liposomes, lipid nanoparticles, and polymeric particles for site-specific delivery. Current-generation nanoplatforms integrate carrier design, surface functionalization, and stimuli-responsive mechanisms to release therapeutics precisely when and where needed, regulating release based on disease biology. Nanocarriers such as lipid-based and polymeric systems have become essential in enabling many potent yet poorly soluble, unstable, or rapidly excreted drugs to reach therapeutic concentrations at target sites. These advanced delivery systems significantly improve pharmacokinetics, biodistribution, safety profiles, and patient outcomes, converting biopharmaceutically challenged molecules into viable medicines.

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality despite advances in resection, transplantation, and systemic treatments. Key limitations including tumor recurrence, drug resistance, toxicity, and tumor heterogeneity necessitate innovative therapeutic approaches. Researchers at Macau University of Science and Technology, led by Qian Ding and Yi Zhun Zhu, published a comprehensive review in Drug Design, Development and Therapy examining prodrug design strategies tailored to HCC's unique tumor microenvironment (TME). Prodrugs are pharmacologically inactive derivatives that convert to active drugs through chemical or enzymatic processes after administration. This analysis evaluates prodrugs activated by specific TME signals including acidity, redox imbalance, hypoxia, disease-associated enzymes, and lactate-coupled processes. The review distinguishes between true prodrugs and responsive carrier systems containing unmodified active drugs or imaging probes. By employing a clinically anchored framework, the study assesses whether proposed activation mechanisms effectively discriminate HCC from adjacent healthy, inflamed, fibrotic, or cirrhotic tissue, offering insights into personalized treatment strategies for improved therapeutic outcomes and reduced off-target toxicity.

# Professional Summary Researchers from China Medical University have published a comprehensive review examining the delivery of therapeutic agents to the tumor microenvironment, with particular focus on RNA interference-based cancer therapy. The study, led by Kefeng Wang and Dongyan Liu, explores small interfering RNA (siRNA) as a promising cancer treatment strategy. siRNA functions by recognizing and degrading complementary messenger RNAs in a sequence-specific manner, effectively silencing disease-causing genes at the post-transcriptional level. However, significant obstacles currently limit clinical application: siRNA exhibits poor physiological stability, rapid enzymatic degradation, inefficient cellular membrane penetration, and insufficient targeting specificity. This review synthesizes research progress on overcoming these delivery challenges through advanced nanomedicine approaches. Understanding effective delivery mechanisms for siRNA and other therapeutic molecules to tumor microenvironments is critical for advancing personalized cancer therapeutics and improving treatment efficacy while minimizing off-target effects. The work contributes essential insights for researchers developing next-generation RNA-based cancer interventions.

Cancer drug resistance remains a critical clinical challenge limiting durable treatment responses across oncology. This comprehensive review systematically examines resistance mechanisms across 22 cancer types, distinguishing between intrinsic resistance, where tumors fail initial treatment response, and acquired resistance emerging during or after therapy. Key molecular mechanisms identified include compensatory pathway activation, phenotypic plasticity, immune evasion, enhanced DNA damage repair, and survival of drug-tolerant persister cells. The analysis spans major therapeutic modalities including chemotherapy, targeted therapy, and immunotherapy, supported by clinical trial evidence. To address these challenges, the review presents emerging strategies such as rational drug combinations, microbiome modulation, adaptive and intermittent therapies, and advanced drug delivery systems. Additionally, cutting-edge research tools are transforming resistance investigation, including single-cell and spatial multiomic profiling, patient-derived tumor organoid and xenograft models, and artificial intelligence-powered predictive analytics. By integrating molecular, cellular, and clinical insights, this strategic framework advances understanding of cancer drug resistance mechanisms and provides actionable approaches for precision oncology development, ultimately improving long-term patient survival outcomes.

The immune microenvironment critically influences disease progression and therapeutic resistance across cancers, inflammatory conditions, and autoimmune disorders. Despite advances in immunotherapy and targeted treatments, their effectiveness remains limited by biological barriers, poor tissue penetration, and immune evasion. Addressing these challenges requires integrating artificial intelligence, multi-omics analysis, and advanced nanomedicine. Machine learning and bioinformatics identify novel biomarkers and therapeutic targets from large datasets, while AI-assisted radiomics and deep learning enable precise patient stratification and real-time treatment monitoring. Sophisticated nanocarrier systems—including lipid nanoparticles, stimulus-responsive polymers, and extracellular vehicles—deliver therapeutics and immunomodulators directly to disease microenvironments. This research initiative bridges computational science, clinical oncology and immunology, and materials science to establish a translational pipeline. It emphasizes using AI and bioinformatics to identify microenvironment vulnerabilities and deploying precision nanomedicines to target these weaknesses. Priority areas include AI-guided drug delivery using machine learning and single-cell sequencing, tumor microenvironment remodeling to overcome immunosuppression and checkpoint inhibitor resistance, and radiomics-based treatment evaluation through multimodal deep learning models.

Redox-modulating metallic nanoparticles represent an emerging frontier in cellular therapeutics, with researchers increasingly recognizing their potential to modulate oxidative stress pathways. This comprehensive review examines the mechanistic foundations underlying the pharmacological activity of these nanoparticles, published in Naunyn-Schmiedeberg's Archives of Pharmacology in August 2026. The article synthesizes current understanding of how metallic nanoparticles—including gold, silver, and iron oxide variants—interact with cellular redox systems to influence therapeutic outcomes. By elucidating the mechanisms through which these particles modulate reactive oxygen species production and antioxidant defenses, the review provides critical insights for therapeutic application development. The significance of this work lies in establishing evidence-based frameworks for leveraging redox modulation in treating diseases characterized by oxidative imbalance, including neurodegenerative conditions, cancer, and inflammatory disorders. Understanding these mechanistic pathways enables rational design of nanoparticle-based therapeutics with enhanced efficacy and reduced off-target effects, positioning redox-modulating metallic nanoparticles as promising candidates for next-generation pharmaceutical interventions.

Liposome-Exosome Hybrid Nanoparticles (LEHNs) represent an advanced biogenic delivery system that combines synthetic liposomes with naturally-derived exosomes to overcome current challenges in targeted drug and gene delivery. This hybrid approach leverages the high payload capacity and stability of liposomes with the inherent biocompatibility, low immunogenicity, and natural cell-targeting capabilities of exosomes. LEHNs enable efficient packaging and delivery of large therapeutic nucleic acids and gene manipulation tools into difficult-to-transfect cell types, while minimizing systemic toxicity and off-target effects. Key applications include tumor-targeted drug accumulation through engineering exosomal membrane proteins and therapeutic delivery to progenitor or immune cells for tissue repair and immune modulation. The technology demonstrates superior biomimetic specificity, enhanced payload capacity, reduced immunogenicity, and robust stability compared to conventional delivery systems. Success requires precise control over membrane fusion processes and careful optimization of liposome composition to maximize cargo loading while reducing cytotoxicity, making LEHNs a promising advancement for accelerating translational medicine projects and achieving superior cell-specific therapeutic delivery.

Despite decades of cancer vaccine research, therapeutic development has faced significant efficacy challenges, with Sipuleucel-T as the sole FDA-approved option until recently. However, personalized mRNA vaccines—specifically Moderna's mRNA-4157 and BioNTech's autogene cevumeran—have demonstrated substantial clinical promise, achieving notable reductions in recurrence risk and improved survival outcomes across multiple cancer types. These personalized vaccines harness patient-specific tumor neoantigens to generate targeted immune responses. The field encompasses diverse platforms including DNA-, mRNA-, peptide-, dendritic cell-, and whole-cell-based approaches, each confronting obstacles such as tumor heterogeneity and immunosuppressive microenvironments. Advanced delivery systems utilizing lipid-polymer hybrids, biomimetic membranes, and stimulus-responsive nanovaccines enhance lymph node targeting and dendritic cell activation. Integration with artificial intelligence for antigen selection and multiomics for patient stratification streamlines vaccine development, while combination strategies with checkpoint inhibitors strengthen durability. Clinical evidence increasingly supports efficacy in melanoma and pancreatic cancer, positioning personalized cancer vaccines as transformative precision immunotherapies that shift oncology from reactive treatment toward proactive, personalized cancer control.

Acidosis plays a critical role in cancer progression and malignancy rather than being merely a secondary effect. This comprehensive review examines how acidosis drives and selects for malignant phenotypes, including enhanced invasion, metastasis, chemoresistance, immune suppression, and metabolic reprogramming. The authors, affiliated with institutions in Yantai, China, analyze existing small-molecule and antibody-based therapies targeting pH regulation, while highlighting the therapeutic potential of nanotechnology and pH-responsive drug delivery systems. The review emphasizes that cancer cells generate acidic microenvironments through the Warburg Effect—high glucose consumption producing substantial lactic acid—creating extracellular pH levels between 5.5 and 7.0. Tumor cells maintain intracellular pH through rapid buffering processes involving acid consumption and cytoplasmic-to-organelle transfer. The authors argue that nanomaterials offer significant advantages for precision cancer therapy by enabling pH-responsive systems to target acidic tumor microenvironments. Integrating artificial intelligence with nanotechnology promises to accelerate screening of pH-responsive systems, facilitating personalized therapeutic development while reducing adverse reactions in cancer treatment.

This open-access review, published in August 2026, examines critical chemistry, manufacturing, and controls considerations essential for translating mRNA lipid nanoparticle (LNP) technology from research to clinical applications. The article addresses the complex chemistry underlying LNP formulations, which are crucial delivery systems for mRNA-based therapeutics. It explores manufacturing processes and quality control measures necessary to ensure consistent, safe, and effective production of mRNA-LNP therapeutics. The review synthesizes current knowledge on formulation optimization, process scalability, and analytical characterization methods required for regulatory compliance. By comprehensively addressing these technical challenges, the article provides guidance for translating promising mRNA-LNP candidates into viable pharmaceutical products. This work is particularly significant given the rapid expansion of mRNA therapeutics following COVID-19 vaccines' success, where robust manufacturing standards and controls directly impact drug safety, efficacy, and accessibility. The review serves as a valuable resource for researchers, manufacturers, and regulatory bodies navigating the complex landscape of mRNA-LNP development and commercialization.

Researchers Singh, Swain, Shamim, Phanindra, and Dikhit have developed an injectable thermoresponsive delivery system designed to improve breast cancer treatment outcomes. The novel formulation combines poly(lactic-co-glycolic acid) nanoparticles—commonly known as PLGA nanoparticles—with an in situ gel matrix to enable sustained, controlled delivery of exemestane, an aromatase inhibitor used in hormone-receptor-positive breast cancer therapy. The system operates as a thermoresponsive injectable, meaning it transitions from liquid to gel form at body temperature, allowing for prolonged drug release at the tumor site. The researchers characterized the formulation extensively and employed the HET-CAM assay, a validated in vitro vascularization test, to evaluate biocompatibility and irritancy profiles. This delivery approach addresses a critical clinical challenge: maintaining therapeutic exemestane concentrations while minimizing systemic exposure and associated side effects. By enabling sustained local drug delivery, this technology could enhance treatment efficacy, improve patient compliance through reduced dosing frequency, and potentially reduce adverse reactions compared to conventional oral exemestane administration.

Researchers from Chinese medical institutions have developed a novel bioresponsive nanocarrier system called HA@Cel/NPs designed to treat the progression from ulcerative colitis through colitis-associated colorectal cancer to colon cancer. The nanocarriers utilize hyaluronic acid functionalization combined with dual enzyme and reactive oxygen species-triggered release mechanisms to deliver celastrol, a compound with limited oral bioavailability. The system incorporates CD44-mediated active targeting to achieve lesion-specific accumulation. The nanoparticles demonstrated uniform size of approximately 77 nanometers with good stability over 14 days. Comprehensive in vitro studies confirmed enhanced cellular uptake, anti-inflammatory activity, and anticancer efficacy. In vivo experiments using mouse models of UC, CAC, and colon cancer showed promising therapeutic outcomes, with additional benefits observed when combined with anti-PD-L1 immunotherapy in the colon cancer model. This multifunctional approach addresses the critical gap in current oral nanocarrier therapies by simultaneously targeting multiple pathological stages through a single intelligent delivery platform, potentially transforming treatment strategies for this disease continuum.

Prostate cancer presents significant clinical challenges due to difficulties in early detection, tumor heterogeneity, therapeutic resistance, and metastatic progression. A comprehensive review published in the International Journal of Nanomedicine examines how engineered multimodal nanomaterials offer promising solutions for prostate cancer theranostics. These nanomaterial platforms integrate multiple functionalities including molecular imaging, biomarker detection, targeted drug delivery, and multimodal therapeutic approaches, while simultaneously enabling therapeutic response assessment. By combining diagnostic and therapeutic capabilities within single nanostructures, these materials address critical gaps in current prostate cancer management. The review, authored by Wang and colleagues from institutions across China including Kunming Medical University and Southern Medical University, synthesizes recent advances in major nanomaterial platforms for prostate cancer applications. This multimodal approach represents a significant advancement in precision oncology, potentially improving early detection rates, personalizing treatment strategies, and monitoring treatment efficacy in prostate cancer patients, ultimately enhancing clinical outcomes and patient care quality.

In situ cancer vaccination, or intratumoral immunotherapy, represents an innovative approach that transforms tumors into endogenous vaccine platforms by leveraging their complete antigenic repertoire, including tumor-associated antigens, neoantigens, and post-translationally modified epitopes. Unlike conventional vaccines requiring predefined targets and complex manufacturing, this strategy elicits robust polyclonal cytotoxic T-cell responses and facilitates epitope spreading, thereby reducing immune escape. The therapeutic mechanism involves coordinated activation of multiple immune pathways, including immunogenic apoptosis, pyroptosis, necroptosis, and ferroptosis, which release tumor antigens and danger-associated molecular patterns that promote dendritic-cell activation and durable T-cell responses. Potent adjuvants and advanced delivery platforms enhance this immunological crosstalk while remodeling the immunosuppressive tumor microenvironment. However, clinical translation faces challenges including inconsistent induction of immunogenic cell death, suboptimal intratumoral therapeutic retention, and T-cell infiltration barriers. Recent advances in nanomedicine-enabled delivery systems and combinatorial strategies with immune checkpoint blockade are overcoming these obstacles, positioning in situ vaccination as a broadly applicable, patient-tailored immunotherapy capable of generating durable systemic antitumor immunity.

This open-access review article, published in August 2026 in Pharmaceutical Research, examines stimulus-responsive polymeric carriers designed for gene delivery applications. The research addresses a critical challenge in therapeutic nucleic acid delivery: balancing effective endosomal escape with controlled nucleic acid release. Stimulus-responsive polymers represent an advanced approach to gene therapy, as they can dynamically respond to physiological or external triggers such as pH changes, temperature fluctuations, or redox conditions within cellular environments. These polymeric systems enable nucleic acids to bypass cellular barriers while ensuring precise release of genetic cargo at target sites. The article comprehensively reviews current stimulus-responsive polymer technologies, their mechanisms of action, and their efficacy in gene delivery systems. By analyzing the delicate equilibrium between endosomal escape capabilities and nucleic acid release kinetics, this review provides valuable insights for developing next-generation gene delivery vehicles with improved therapeutic potential and reduced off-target effects.

Tumor heterogeneity represents a fundamental cancer hallmark driving progression, metastasis, and therapeutic resistance through genomic instability, clonal evolution, and cancer stem cell plasticity amplified by microenvironmental interactions. While conventional therapies eliminate certain tumor populations, resistant subclones frequently cause disease relapse. Advanced techniques including single-cell multi-omics, spatial transcriptomics, and liquid biopsy now enable comprehensive analysis of tumor heterogeneity across molecular, cellular, spatial, and temporal dimensions, revealing real-time evolutionary dynamics. This review synthesizes current understanding of tumor heterogeneity's origins and mechanisms, from cellular sources to microenvironmental manifestations and treatment resistance causes. It examines emerging therapeutic paradigms targeting clonal cooperative networks, modulating epigenetic plasticity, and reprogramming metabolic adaptations. The article emphasizes precision medicine advancement through integrated multi-omics data and dynamic monitoring technologies, advocating reconceptualization of cancer as an evolving ecosystem rather than static cells. Understanding the full extent of genetic, epigenetic, and transcriptional variation within and between tumors is essential for developing effective strategies to overcome heterogeneity-driven therapeutic challenges.

This open-access review examines cutting-edge biotechnological approaches for treating diabetic foot ulcers through biomaterial-based strategies. Published in August 2026 in Biotechnology for Sustainable Materials, the article synthesizes current research on drug delivery systems designed to enhance angiogenesis and tissue regeneration in diabetic wound healing. Diabetic foot ulcers represent a significant clinical challenge, often leading to severe complications and amputation when inadequately managed. The review explores how advanced biomaterials serve as platforms for controlled drug delivery, promoting new blood vessel formation and accelerating tissue repair processes. By integrating sophisticated delivery mechanisms with regenerative medicine principles, these approaches offer promising therapeutic potential to improve healing outcomes. The article's comprehensive analysis of biomaterial-based interventions addresses a critical gap in current diabetic ulcer treatment options, highlighting how nanotechnology and engineered scaffold systems can optimize therapeutic efficacy. This research is essential for healthcare professionals and biotechnology researchers seeking innovative solutions to reduce morbidity and improve quality of life for patients suffering from this prevalent diabetes-related complication.

Hepatotropic nanomedicine represents a promising approach to address the growing burden of liver diseases, including cirrhosis, fibrosis, viral hepatitis, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and hepatocellular carcinoma (HCC). Conventional drug delivery systems frequently fail due to low bioavailability, poor water solubility, and hepatic metabolism limitations. This comprehensive review, published in the International Journal of Nanomedicine by researchers from Shuyang Benevolent Hospital, examines various liver-targeted nanocarrier systems designed to overcome these challenges. The review encompasses polymeric, lipid, inorganic, biomimetic, and nucleic acid-based platforms that employ both passive and active targeting strategies. These systems leverage the liver's unique properties, including its cellular diversity, fenestrated sinusoidal endothelium, and receptor-mediated uptake mechanisms, while also exploiting tumor microenvironment characteristics such as acidity and oxidative stress. The article addresses targeted delivery to hepatocytes, Kupffer cells, hepatic stellate cells, and HCC cells, offering tailored therapeutic solutions for specific liver pathologies and addressing the significant global health burden of liver disease.